The effectiveness of either ustekinumab or vedolizumab in 239 patients with Crohn's disease refractory to anti-tumour necrosis factor-Reference-Cited by-同舟云学术

The effectiveness of either ustekinumab or vedolizumab in 239 patients with Crohn's disease refractory to anti-tumour necrosis factor

Published:2020-04-06 Issue:10 Volume:51 Page:948-957
ISSN:0269-2813
Container-title:Alimentary Pharmacology & Therapeutics
language:en
Short-container-title:Aliment Pharmacol Ther

Author:

Alric Hadrien¹^ORCID,Amiot Aurélien²,Kirchgesner Julien³,Tréton Xavier⁴^ORCID,Allez Matthieu⁵,Bouhnik Yoram⁴,Beaugerie Laurent³,Carbonnel Franck¹,Meyer Antoine¹^ORCID

Affiliation:

1. Assistance Publique-Hôpitaux de Paris; Hôpital Bicêtre; Université Paris Saclay; Le Kremlin Bicêtre France

2. Assitance-Publique-Hôpitaux de Paris; Hôpitaux Universitaires Henri Mondor; Université Paris Est Créteil; Créteil France

3. Assistance Publique-Hôpitaux de Paris; Hôpital Saint-Antoine; Sorbonne Université; Paris France

4. Assistance Publique-Hôpitaux de Paris; Hôpital Beaujon; Université de Paris; Clichy France

5. Assistance Publique-Hôpitaux de Paris; Hôpital Saint-Louis; Université de Paris; Paris France

Publisher

Wiley

Subject

Pharmacology (medical),Gastroenterology,Hepatology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/apt.15706/fullpdf

Reference43 articles.

1. Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies;Ng;Lancet,2017

2. Prediction of complicated disease course for children newly diagnosed with Crohn’s disease: a multicentre inception cohort study;Kugathasan;Lancet,2017

3. Therapeutic management of inflammatory bowel disease in real-life practice in the current era of anti-TNF agents: analysis of the French administrative health databases 2009-2014;Kirchgesner;Aliment Pharmacol Ther,2017

4. Systematic review: predicting and optimising response to anti-TNF therapy in Crohn’s disease - algorithm for practical management;Ding;Aliment Pharmacol Ther,2016

5. Loss of response and need for adalimumab dose intensification in Crohnʼs disease: a systematic review;Billioud;Am J Gastroenterol,2011

Cited by 79 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Controversies in the management of anti-TNF therapy in patients with Crohn’s disease: a Delphi consensus;BMJ Open Gastroenterology;2024-01

2. Comparative effectiveness of ustekinumab vs. vedolizumab for anti-TNF-naïve or anti-TNF-exposed Crohn's disease: a multicenter cohort study;eClinicalMedicine;2023-12

3. scDrugPrio: A framework for the analysis of single-cell transcriptomics to address multiple problems in precision medicine in immune-mediated inflammatory diseases;2023-11-13

4. Effectiveness of vedolizumab and ustekinumab as second biologic agent in achieving target outcomes in tumor necrosis factor antagonists experienced patients with inflammatory bowel disease (enroll-ex study);Frontiers in Pharmacology;2023-10-09

5. Clinical guidelines. Crohn’s disease (К50), adults;Koloproktologia;2023-09-21